Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 221 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Impaired Glucose Metabolism Clear all
Completed Not applicable Interventional Results available

Intervention to Reduce Sedentary Time

NCT02878486
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Jawbone Up, Physical Activity Education, ActivPAL
Device · Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2019 · Synced Jul 23, 2026, 11:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Health Effects of Liposuction in Overweight Women With Elevated Insulin Levels, Impaired Glucose Tolerance and/or Type 2 Diabetes

NCT00005760
View directory record Official record
Conditions
Glucose Intolerance, Hyperinsulinemia, Diabetes Mellitus, Non Insulin Dependent, Obesity
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 11:17 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment

NCT02827708
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
60
States / cities
Tuscumbia, Alabama • Bermuda Dunes, California • Concord, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Jul 23, 2026, 11:17 AM EDT
Terminated Phase 4 Interventional Results available

Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment

NCT05552859
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Renal Impairment
Interventions
Insulin glargine 300 U/mL, Insulin degludec 100 U/mL
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
32
States / cities
Yuma, Arizona • Buena Park, California • Canyon Country, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Jul 23, 2026, 11:17 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Polycystic Ovary Syndrome (PCOS) and Sleep Apnea

NCT00203996
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Obstructive Sleep Apnea
Interventions
continuous positive airway pressure (CPAP), depot leuprolide plus estrogen/progestin replacement, pioglitazone, REM frag, SWS supp
Device · Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Jul 23, 2026, 11:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dose-dependent Effect of Grape Seed Extract on Glucose Control in People With Impaired Glucose Tolerance

NCT02254317
View directory record Official record
Conditions
Impaired Glucose Tolerance
Interventions
0 mg placebo, 300 mg GSE, 600 mg GSE, 900 mg GSE
Dietary Supplement
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
40 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Jul 23, 2026, 11:17 AM EDT
Active, not recruiting Phase 3 Interventional

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

NCT06297603
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
28
States / cities
Huntsville, Alabama • Sun City West, Arizona • Apple Valley, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 11:17 AM EDT
Completed Phase 4 Interventional

Dapagliflozin Treatment in Type 2 Diabetes

NCT04620590
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Impaired Renal Function
Interventions
Dapagliflozin 10 MG [Farxiga]
Drug
Lead sponsor
Emerald Clinical Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Jul 23, 2026, 11:17 AM EDT
Completed Phase 2 Interventional

SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days)

NCT00438568
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Regular Insulin, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
55 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 13, 2012 · Synced Jul 23, 2026, 11:17 AM EDT
Completed Not applicable Interventional Results available

D Vitamin Intervention in VA

NCT01375660
View directory record Official record
Conditions
Impaired Fasting Glucose, Impaired Glucose Tolerance, Vitamin D Insufficiency
Interventions
Placebo, 50K vitamin D2
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
35 Years to 85 Years · Male only
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Jul 23, 2026, 11:17 AM EDT
Completed Not applicable Interventional

Dietary Interventions in Prediabetes

NCT01729078
View directory record Official record
Conditions
Impaired Fasting Glucose, Pre Diabetes, Liver Fat
Interventions
Dietary intervention
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 28, 2015 · Synced Jul 23, 2026, 11:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Metformin and Muscle in Insulin-resistant Older Veterans

NCT01804049
View directory record Official record
Conditions
Prediabetes
Interventions
metformin, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Jul 23, 2026, 11:17 AM EDT
Terminated No phase listed Observational

Detection and Treatment of Endocrine Abnormalities in Childhood Cancer Survivors and Hematopoietic Stem Cell Transplant Recipients

NCT00504218
View directory record Official record
Conditions
Hypopituitarism, Hypogonadism, Thyroid Dysfunction, Bone Diseases, Metabolic
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 24 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2018 · Synced Jul 23, 2026, 11:17 AM EDT
Completed Phase 4 Interventional Results available

Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes

NCT02964585
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
George Washington University
Other
Eligibility
30 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Jul 23, 2026, 11:17 AM EDT
Completed Not applicable Interventional Results available

Sleep Loss and Mechanisms of Impaired Glucose Metabolism

NCT00555750
View directory record Official record
Conditions
Primary Insomnia
Interventions
eszopiclone, placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
25 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced Jul 23, 2026, 11:17 AM EDT
Active, not recruiting Phase 4 Interventional

The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans

NCT03938389
View directory record Official record
Conditions
PreDiabetes, Impaired Glucose Tolerance, Obesity, Blood Pressure
Interventions
Sacubitril-Valsartan Tab 97-103 MG, Valsartan 160mg, Placebo Oral Tablet
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Jul 23, 2026, 11:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mitochondrial Impairment in Muscle Insulin Resistance

NCT00222924
View directory record Official record
Conditions
Diabetes, Obesity
Interventions
weight loss/ exercise
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
30 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2007 · Synced Jul 23, 2026, 11:17 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Low-calorie Diet in Isolated Impaired Fasting Glucose

NCT06451055
View directory record Official record
Conditions
Isolated Impaired Fasting Glucose
Interventions
Low-calorie diet, Routine dietary and physical activity habits
Behavioral
Lead sponsor
Emory University
Other
Eligibility
35 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 23, 2026, 11:17 AM EDT
Completed Phase 4 Interventional Results available

Linagliptin's Effect on CD34+ Stem Cells

NCT02467478
View directory record Official record
Conditions
Type 2 Diabetes, Impaired Renal Function
Interventions
Linagliptin, Placebo
Drug
Lead sponsor
George Washington University
Other
Eligibility
30 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Jul 23, 2026, 11:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function

NCT00845182
View directory record Official record
Conditions
Type 2 Diabetes, Healthy, Impaired Glucose Tolerance
Interventions
Pioglitazone, Exenatide, Pioglitazone and Exenatide
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Jul 23, 2026, 11:17 AM EDT
Completed Not applicable Interventional

Lifestyle Interventions to Reduce Diabetes Risk

NCT00006162
View directory record Official record
Conditions
Glucose Intolerance, Diabetes Mellitus, Type 2
Interventions
exercise and diet
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1999
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Jul 23, 2026, 11:17 AM EDT
Recruiting Not applicable Interventional

Closed Loop and Education for Hypoglycemia Awareness Restoration

NCT06325202
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Omnipod 5 or Medtronic 780G, My HypoCOMPaSS Education, HARPdoc Education
Device · Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
La Jolla, California • Orlando, Florida • Lexington, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jul 23, 2026, 11:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

DELPHI in Subjects at Risk for Stroke and Dementia

NCT03884647
View directory record Official record
Conditions
Stroke, Hypertension, Diabete Mellitus, Dyslipidemias, Sleep Disorder, Smoking, Overweight and Obesity, Familial Alzheimer Disease, Atrial Fibrillation, Cardiac Disease, Cognitive Impairment, Transient Ischemic Attack
Interventions
DELPhI system
Device
Lead sponsor
QuantalX Neuroscience
Industry
Eligibility
50 Years to 75 Years
Enrollment
335 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Walnut Creek, California • Atlanta, Georgia • Norwood, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Jul 23, 2026, 11:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adults

NCT02335021
View directory record Official record
Conditions
Impairment of Oral Perception, Insulin Resistance
Interventions
Sucralose, Sucrose, Sucralose + maltodextrin, Sucralose + Sucrose
Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
23 Years to 45 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Jul 23, 2026, 11:17 AM EDT